Amgen’s Growth Story Relies Mainly On Continuing Plot Lines
Forecasts Mid-Single-Digit Revenue CAGR Through 2030
Established brands Repatha and Otezla, new launches Lumakras and Tezspire, and the Amjevita-led biosimilars portfolio will provide most of the company’s growth through the end of this decade.
